Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hormonal treatments and epithelial ovarian cancer risk.
Auranen A, Hietanen S, Salmi T, Grénman S. Auranen A, et al. Among authors: hietanen s. Int J Gynecol Cancer. 2005 Sep-Oct;15(5):692-700. doi: 10.1111/j.1525-1438.2005.00131.x. Int J Gynecol Cancer. 2005. PMID: 16174215 Free article. Review.
[Update on current care guidelines: ovarian cancer].
Leminen A, Auranen A, Bützow R, Hietanen S, Komulainen M, Kuoppala T, Mäenpää J, Puistola U, Vuento M, Vuorela P, Yliskoski M. Leminen A, et al. Among authors: hietanen s. Duodecim. 2012;128(12):1300-1. Duodecim. 2012. PMID: 22822606 Review. Finnish.
Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.
Pikkusaari S, Tumiati M, Virtanen A, Oikkonen J, Li Y, Perez-Villatoro F, Muranen T, Salko M, Huhtinen K, Kanerva A, Koskela H, Tapper J, Koivisto-Korander R, Joutsiniemi T, Haltia UM, Lassus H, Hautaniemi S, Färkkilä A, Hynninen J, Hietanen S, Carpén O, Kauppi L. Pikkusaari S, et al. Among authors: hietanen s. Clin Cancer Res. 2023 Aug 15;29(16):3110-3123. doi: 10.1158/1078-0432.CCR-22-3156. Clin Cancer Res. 2023. PMID: 36805632 Free PMC article.
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, Bradley WH, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A. O'Cearbhaill RE, et al. Among authors: hietanen s. Gynecol Oncol. 2022 Jul;166(1):36-43. doi: 10.1016/j.ygyno.2022.04.012. Epub 2022 May 9. Gynecol Oncol. 2022. PMID: 35550709 Free PMC article. Clinical Trial.
HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma.
Koskela H, Li Y, Joutsiniemi T, Muranen T, Isoviita VM, Huhtinen K, Micoli G, Lavikka K, Marchi G, Hietanen S, Virtanen A, Hautaniemi S, Oikkonen J, Hynninen J. Koskela H, et al. Among authors: hietanen s. Gynecol Oncol. 2024 Jan;180:91-98. doi: 10.1016/j.ygyno.2023.11.027. Epub 2023 Dec 6. Gynecol Oncol. 2024. PMID: 38061276 Free article. Clinical Trial.
Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer.
Zhang K, Erkan EP, Jamalzadeh S, Dai J, Andersson N, Kaipio K, Lamminen T, Mansuri N, Huhtinen K, Carpén O, Hietanen S, Oikkonen J, Hynninen J, Virtanen A, Häkkinen A, Hautaniemi S, Vähärautio A. Zhang K, et al. Among authors: hietanen s. Sci Adv. 2022 Feb 25;8(8):eabm1831. doi: 10.1126/sciadv.abm1831. Epub 2022 Feb 23. Sci Adv. 2022. PMID: 35196078 Free PMC article.
112 results